Proactiveinvestors recommends
Additional Information
Market: XETRA
Sector: General Financial
EPIC: NNS
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Nanostart AG
www.nanostart.de

We undertake equity investments in emerging nanotechnology companies which hold the potential to deliver extraordinary long-term growth. The typical size of our investments is between one and ten million Euros.

Full Nanostart AG profile here
Is NNS a Buy, Sell or Hold?Get your FREE analysis of NNS
Pdf

Nanostart's MagForce commercializes NanoTherm therapy, establishes treatment centre

12th Jul 2011, 8:17 pm by Olivia D'Orazio

Nanotechnology investor Nanostart (OTC:NASRY) said today that portfolio company MagForce Nanotechnologies has established a treatment centre for its NanoTherm therapy for brain tumours at Charite-Universitatsmedizin, in Berlin, beginning commercialization of its products.

MagForce is a medical technology company focused on nanomedicine in oncology. The company has received EU approval for its medical devices, which use magnetic nanoparticles for the treatment of brain tumors, injected in a procedure similar to a biopsy.

The treatment is carried out in a magnetic field applicator, or NanoActivator, and depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation, the company said.

This therapy has the potential to improve the survival for patients with recurrent glioblastoma, an especially malignant type of brain tumor, Nanostart added.

"I am pleased that we have accomplished this first step in making NanoTherm therapy available to brain tumor patients,” said MagForce chief executive, Peter Heinrich.

"There have been many challenges associated with introducing a completely new therapeutic approach to the medical community; therefore, the initial roll-out has taken longer than expected."

MagForce said it is in discussions with medical institutions to establish more treatment centres, and is working to make the therapy available internationally.

Founder of MagForce, Andreas Jordan, said they are pursuing further development of NanoTherm therapy for the treatment of prostate and pancreatic carcinomas.

“NanoTherm therapy has enormous therapeutic potential to treat a variety of solid tumors, and we are just at the beginning,” Jordan added.

Frankfurt-based Nanostart provides venture capital financing for nanotechnology companies in various growth phases, with a focus on sectors such as cleantech, life sciences and IT and electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is also partnered with the Singaporean government.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.